Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study
Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc disease has been completed. This means that the target number of evaluable patients in the study has now been reached twelve months after receiving treatment with STA363. The Phase 2b study, aimed at evaluating the pain relief of the drug candidate STA363, has been successfully concluded with high quality, good compliance and a low patient dropout rate. The company is following the previously communicated timeline and expects to